The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Outcomes of 3-weekly doxorubicin and cyclophosphamide followed by paclitaxel (AC/T) in a randomized trial (RCT) compared to a case-control matched British Columbia (BC) breast cancer population.
Sheridan Marie Wilson
No relevant relationships to disclose
Yvonne Zheng
No relevant relationships to disclose
Judy-Anne W. Chapman
No relevant relationships to disclose
Margot J. Burnell
No relevant relationships to disclose
Caroline Speers
No relevant relationships to disclose
Emily Baxter
No relevant relationships to disclose
Scott Tyldesley
No relevant relationships to disclose
Lois E. Shepherd
No relevant relationships to disclose
Karen A. Gelmon
No relevant relationships to disclose
Caroline A. Lohrisch
No relevant relationships to disclose